TY - JOUR

T1 - Psychometric evaluation of a daily gastro-oesophageal reflux disease symptom measure

AU - Bytzer, Peter

AU - Reimer, Christina

AU - Smith, Gary

AU - Anatchkova, Milena D.

AU - Hsieh, Ray

AU - Wilkinson, Joanne

AU - Thomas, S. Jane

AU - Lenderking, William R.

PY - 2017

Y1 - 2017

N2 - Objective: The objective of this study was to evaluate the validity of the Heartburn Reflux Dyspepsia Questionnaire (HRDQ), a newly developed measure of gastro-oesophageal reflux disease (GORD) symptoms. Specifically, the HRDQ was developed for patients, who still experience symptoms with proton pump inhibitor (PPI) treatment. Material and methods: The psychometric properties of HRDQ were evaluated based on data from two clinical trials of patients with GORD with a partial response to PPIs, one from the UK and one from Denmark and Germany. Results: The HRDQ had good internal consistency (Cronbach’s alpha range.83–.88) and test–retest reliability (intraclass correlation coefficient range.71–.90). Convergent and discriminant validity were supported by high correlations with ReQuest™ and ability to differentiate between groups based on ReQuest™ cut-off values. Responsiveness of HRDQ was demonstrated by moderate to high correlations with ReQuest™ change scores and time with symptoms. An HRDQ cut-off value of 0.70 for definition of ‘bad day’ was also evaluated. Conclusions: Based on existing evidence, the HRDQ is a valid and reliable measure of GORD symptoms that can be used as a study outcome in clinical trials.

AB - Objective: The objective of this study was to evaluate the validity of the Heartburn Reflux Dyspepsia Questionnaire (HRDQ), a newly developed measure of gastro-oesophageal reflux disease (GORD) symptoms. Specifically, the HRDQ was developed for patients, who still experience symptoms with proton pump inhibitor (PPI) treatment. Material and methods: The psychometric properties of HRDQ were evaluated based on data from two clinical trials of patients with GORD with a partial response to PPIs, one from the UK and one from Denmark and Germany. Results: The HRDQ had good internal consistency (Cronbach’s alpha range.83–.88) and test–retest reliability (intraclass correlation coefficient range.71–.90). Convergent and discriminant validity were supported by high correlations with ReQuest™ and ability to differentiate between groups based on ReQuest™ cut-off values. Responsiveness of HRDQ was demonstrated by moderate to high correlations with ReQuest™ change scores and time with symptoms. An HRDQ cut-off value of 0.70 for definition of ‘bad day’ was also evaluated. Conclusions: Based on existing evidence, the HRDQ is a valid and reliable measure of GORD symptoms that can be used as a study outcome in clinical trials.

KW - Gastro-oesophageal reflux disease

KW - GORD

KW - RDQ

KW - reflux

KW - ReQuest™

U2 - 10.1080/00365521.2016.1250282

DO - 10.1080/00365521.2016.1250282

M3 - Journal article

C2 - 27826993

AN - SCOPUS:84994881901

VL - 52

SP - 276

EP - 283

JO - Scandinavian Journal of Gastroenterology. Supplement

JF - Scandinavian Journal of Gastroenterology. Supplement

SN - 0085-5928

IS - 3

ER -